Milda | Moderatea | Severea | |
---|---|---|---|
Empiric treatment for Nocardia infection | TMP-SMX 160/800 mg (child 1 mo or older 4 + 20 mg/kg up to 160 + 800 mg) orally, every 12 h | TMP-SMX 160/800 mg (adult >60 kg: 320 + 1600 mg; adult 40 to 60 kg: 240 + 1200 mg; child 1 mo or older: 6 + 30 mg/kg up to 240 + 1200 mg) orally, every 12 h PLUS EITHER ceftriaxone 2 g (child 1 mo or older: 50 mg/kg up to 2 g) IV, daily OR linezolid 600 mg orally, every 12 h (child younger than 12 y: 10 mg/kg up to 600 mg orally, every 8 h) |
TMP-SMX 320/1600 mg (child 1 mo or older: 8 + 40 mg/kg up to 320 + 1600 mg) IV or orally, every 12 h PLUS linezolid 600 mg IV or orally, every 12 h (child younger than 12 y: 10 mg/kg up to 600 mg IV or orally, every 8 h) PLUS EITHER amikacin (adult and child) 20 mg/kg IV daily or 10 mg/kg IV, every 12 h OR imipenem 500 mg (child 15 mg/kg up to 500 mg) IV, every 6 h OR meropenem 2 g (child 40 mg/kg up to 2 g) IV, every 8 h |
Abbreviations: IV, intravenous; TMP-SMX, trimethoprim-sulfamethoxazole.
aMild: nonsevere disease in immunocompetent patients with localized cutaneous disease. Moderate: nonsevere dis-ease in immunocompetent patients with more extensive cutaneous disease, immunocompromised patients with cuta-neous disease, or any patient with mild to moderate pulmonary disease. Severe: central nervous system disease with brain abscess, disseminated disease, and severe pneumonia. Adapted with permission from Mandell et al., eds. [19].